Nidhi Shah

Dr. Nidhi Shah

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2024 in Cells
Verified
Journal Article
Open access
PDF file
Petar BrlekPetar Brlek
Petar Brlek
Luka BulićLuka Bulić
Luka Bulić
MBMatea Bračić
Matea Bračić
PPPetar Projić
Petar Projić
VSVedrana Skaro
Vedrana Skaro
Dragan PrimoracDragan Primorac
Dragan Primorac
The integration of whole genome sequencing (WGS) into all aspects of modern medicine represents the next step in the evolution of healthcare. Using this technology, scientists and physicians can observe the entire human genome comprehensively, generating a plethora of new sequencing data. Modern computational analysis entails advanced algorithms for variant detection, as well as complex models for classification. Data science and machine learning play a crucial role in the processing and interpretation of results, using enormous databases and statistics to discover new and support current genotype–phenotype correlations. In clinical practice, this technology has greatly enabled the development of personalized medicine, approaching each patient individually and in accordance with their genetic and biochemical profile. The most propulsive areas include rare disease genomics, oncogenomics, pharmacogenomics, neonatal screening, and infectious disease genomics. Another crucial application of WGS lies in the field of multi-omics, working towards the complete integration of human biomolecular data. Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing. These technologies, alongside their continued implementation into medical research and practice, show great promise for the future of the field of medicine.

1 May 2018 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
NSNidhi Shah
Nidhi Shah
PSParth S Shah
Parth S Shah
YPYash Y Panchal
Yash Y Panchal
KKKalpesh H Katudia
Kalpesh H Katudia
NKNikunj B Khatri
Nikunj B Khatri
MRMandava V Rao
Mandava V Rao
Background: Germline mutations BRCA1 and BRCA2 contribute almost equally in the causation of breast cancer (BC). The type of mutations in the Indian population that cause this condition is largely unknown. Purpose: In this cohort, 79 randomized BC patients were screened for various types of BRCA1 and BRCA2 mutations including frameshift, nonsense, missense, in-frame and splice site types. Materials and methods: The purified extracted DNA of each referral patient was subjected to Sanger gene sequencing using Codon Code Analyzer and Mutation Surveyor and next-generation sequencing (NGS) methods with Ion torrent software, after appropriate care. Results: The data revealed that 35 cases were positive for BRCA1 or BRCA2 (35/79: 44.3%). BRCA2 mutations were higher (52.4%) than BRCA1 mutations (47.6%). Five novel mutations detected in this study were p.pro163 frameshift, p.asn997 frameshift, p.ser148 frameshift and two splice site single-nucleotide polymorphisms (SNPs). Additionally, four nonsense and one in-frame deletion were identified, which all seemed to be pathogenic. Polymorphic SNPs contributed the highest percentage of mutations (72/82: 87.8%) and contributed to pathogenic, likely pathogenic, likely benign, benign and variant of unknown significance (VUS). Young age groups (20–60 years) had a high frequency of germline mutations (62/82;75.6%) in the Indian population. Conclusion: This study suggested that polymorphic SNPs contributed a high percentage of mutations along with five novel types. Younger age groups are prone to having BC with a higher mutational rate. Furthermore, the SNPs detected in exons 10, 11 and 16 of BRCA1 and BRCA2 were higher than those in other exons 2, 3 and 9 polymorphic sites in two germline genes. These may be contributory for BC although missense types are known to be susceptible for cancer depending on the type of amino acid replaced in the protein and associated with pathologic events. Accordingly, appropriate counseling and treatment may be suggested.

1 July 2018 in Breast Cancer: Targets and Therapy
Verified
Journal Article
Open access
PDF file
PSParth S Shah
Parth S Shah
SMShiva Murarka
Shiva Murarka
AJAnupam Joshi
Anupam Joshi
BMBhavana Mehta
Bhavana Mehta
VPVipal Parmar
Vipal Parmar
JSJacob Sands
Jacob Sands
Introduction: Human epidermal growth factor receptor 2 (HER2) amplification is present in almost 15%–20% of breast cancer tumors, making it an important parameter for testing. The present study was designed to evaluate a chip-based digital PCR (dPCR) system for assessing HER2 amplification from formalin-fixed paraffin-embedded breast carcinoma tissue and to compare this system with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Materials and methods: A total of 84 breast carcinoma tissue samples were analyzed by IHC, FISH, and chip-based dPCR in a blinded manner. Results: All nine IHC-positive and 35 IHC-negative samples had equivalent results with dPCR, taking an amplification ratio threshold of 1.8 as a positive result. Of the 40 IHC equivocal samples, 10 were assessed as positive, 27 as negative, and three as equivocal by dPCR. Conclusion: These results demonstrate that chip-based dPCR is suitable for HER2 amplification detection in formalin-fixed paraffin-embedded samples in a clinical setting, providing the advantages of superior turnaround time, cost-effectiveness, and increased precision with absolute quantification compared with conventional tests such as FISH and IHC. This methodology was especially beneficial in tissue samples with low DNA concentration.

4 June 2026 in European Journal of Human Genetics
Verified
Journal Article
Closed access
HSHadley Stevens Smith
Hadley Stevens Smith
MVMartin Vu
Martin Vu
Tamara DangouloffTamara Dangouloff
Tamara Dangouloff
CSCamille Schubert
Camille Schubert
CLCamille Level
Camille Level
JBJames Buchanan
James Buchanan

21 March 2022 in Research Square
Verified
Preprint
Open access
PDF file
RGRobert Green
Robert Green
NSNidhi Shah
Nidhi Shah
CGCasie A Genetti
Casie A Genetti
TYTimothy Yu
Timothy Yu
BZBethany Zettler
Bethany Zettler
ABAlan H. Beggs
Alan H. Beggs
Genomic sequencing of healthy newborns to screen for medically important genetic information has long been anticipated but data around downstream medical consequences are lacking. Among 159 infants randomized to the sequencing arm in the BabySeq Project, an unanticipated monogenic disease risk (uMDR) was discovered in 18 (11.3%). We assessed uMDR actionability by visualizing scores from a modified ClinGen Actionability SemiQuantitative Metric and tracked medical outcomes in these infants for 3-5 years. All uMDRs scored as highly actionable (mean 9, range: 7-11 on a 0-12 scale) and had readily available clinical interventions. In 4 cases, uMDRs revealed unsuspected genetic etiologies for existing phenotypes, and in the remaining 14 cases provided risk stratification for future surveillance. In 8 cases, uMDRs prompted screening for multiple at-risk family members. These results suggest that actionable uMDRs are more common than previously thought and support ongoing efforts to evaluate population-based newborn genomic screening.

14 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
HSHadley Stevens Smith
Hadley Stevens Smith
MVMartin Vu
Martin Vu
Tamara DangouloffTamara Dangouloff
Tamara Dangouloff
CSCamille Schubert
Camille Schubert
CLCamille Level
Camille Level
JBJames Buchanan
James Buchanan
Affordability and value-for-money are key factors that will inform decisions about implementation of genomic newborn screening (gNBS) as a population-based program. Given the methodological and data-related challenges to evaluating health and economic outcomes of gNBS, there is a need for discussion and knowledge sharing amongst investigators responsible for conducting such evaluations. The International Consortium on Newborn Sequencing (ICoNS) includes academic and commercial gNBS pilot and implementation programs, and the ICoNS Economics Subcommittee assembles health economists who are involved in the evaluation of these programs. This paper summarizes the reported approaches taken by gNBS researchers to assess the health, psychosocial, and economic outcomes of gNBS and provides recommendations for reporting of gNBS economic evaluations developed by an international working group of health economists. We surveyed 12 ICoNS-affiliated project investigators involved in the design of health economics and outcomes evaluation protocols, the results of which were supplemented through ICoNS Economics Subcommittee discussion. Investigators reported making economic evaluation methodological design choices that reflect both the gNBS study design and adaptation to local policy questions and stakeholder input. Investigators reported plans to conduct cost-effectiveness analyses (n = 7, 58%) and/or cost-utility analyses (n = 5, 42%). Recommendations for reporting gNBS economic evaluations include aspects of genetic condition identification, screening and follow-up care pathways, and health and cost outcomes. Going forward, making transparent study design choices and sharing lessons learned could advance understanding of outcomes in a methodologically complex context and inform researchers planning to design similar studies in the future.